RE:RE:RE:RE:Risk / RewardSimply put we contend that only targeting toxic oligomers can you have the efficacy to slow or stop Alzheimer's. Yes they all have an amyloid antibody, but being specific and not targeting monomers and plaque, will in our opinion lead to a better therapeutic. This is where we are now and it's a win or lose situation.